Welcome to the Investor Relations Portal of SynBiotic SE, one of the leading German providers of cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
Ticker Symbol: SBX
Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX
Total number of shares: 2.625.000
Share capital: 2.625.000,00 EUR
Analyst Recommendation Target Price Last Research
Hauck & Aufhäuser BUY 75 EUR May2021
Edison Investment Research RELEASE AUGUST 2021
Alster Research RELEASE JULI 2021
Baader Bank RELEASE JULI 2021
Stifel RELEASE AUGUST 2021
Vision: Europe's #1 ecosystem for solutions based on
cannabinoids and terpenes
Mission: We are building Europe's largest ecosystem for cannabinoid & terpene
based solutions and transform ideas into better brands &
Products for multi-billion markets like pain, sleep & anxiety.
Growth: We grow 75% year on year (20% organic, 55% inorganic).
Strategy: We cover the entire cannabinoid value chain with our buy & build strategy and
consolidate the strongest players in the industry under one roof. SynBiotic SE is divided into the
1) D2C & medical brands
2) Production & Biotech
3) Research & Development
SynBiotic with the legal form SE (European Company or Societas Europaea) has a monistic management model ("one-tier system"). In the monistic system, the management is not institutionally separated from the supervision. Rather, these two functions are performed by one and the same body (board of directors, administrative board).
Serial entrepreneur with over 10 years of experience in scaling profitable businesses. Deep industry expertise from seed to shelf, genetics, extraction methods & analytics like product development. He has been in the cannabinoid industry since 2015.
Chairman of the Board of Directors:
As a serial entrepreneur, his strengths lie in strategy, ops and executive coaching, with particular expertise in post-merger integration and capital market fitness. Sebastian holds a Master's degree in Business Administration with a focus on IT-enabled marketing and human resources.
DR. MARLON BRAUMANN
Member of the Board of Directors
Dr. Marlon Braumann is a serial entrepreneur and one of the founding partners of the European VC fund Elevat3 Capital - an investment fund primarily focused on biotech, medtech and fintech investments. In addition, Mr. Braumann is the founder of the global wildlife foundation AMES Foundation
Member of the Board of Directors
Mr. Hanke has extensive transaction experience (private equity, venture capital, growth capital & PIPE transactions) and has held various interim operational mandates in portfolio management in addition to his investor activities.
SynBiotic SE - Anayst Presentation (May 2021): Download
March 09, 2021: SynBiotic SE: Investment in The Hempany GmbH
December 17, 2020: SynBiotic SE: successfully completes capital increase
November 26, 2020: Resolved to implement a capital increase from authorized capital
*former Ledgertech SE
01. December 2020: Securities Prospectus
18. November 2020: Extraordinary General Meeting
The Extraordinary General Meeting of SynBiotic SE took place on Wednesday, November 18, 2020, at 12:00 noon ( CET).
The Annual General Meeting will be held in July 2021. The exact date and time will be announced.
If you have any further questions, please do not hesitate to contact us. You can reach us by e-mail or directly on the phone. In addition, we will be happy to include you in our IR news service. This way, you will directly receive all information on investor relations topics of SynBiotic SE. For voting rights notifications to the company, please use the contact details below.